Alejandro Moles‐Fernández

A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation

Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara et al. · EMBO Molecular Medicine · 2018 · 263 citations · Full text

Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification

Michael T. Parsons, Emma Tudini, Hongyan Li et al. · Human Mutation · 2019 · 148 citations · Full text

Genetics, Genetic Epidemiology, Pathology +25

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara et al. · Cancer Research · 2022 · 86 citations · Full text

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

Sandra Bonache, I. Esteban, Alejandro Moles‐Fernández et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 65 citations · Full text

Breast Oncology, Cancer Risk, Multigene Panel +8

Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?

Alejandro Moles‐Fernández, Laura Duran-Lozano, Gemma Montalban et al. · Frontiers in Genetics · 2018 · 64 citations · Full text